Expressing concerns over the bureaucratic bottlenecks involved in conducting clinical research and trials in biotechnology sector in India, the industry experts today appealed to the regulatory authorities to stick to the "rule book" rather than "subjectivity".
Yesterday, in a strongly worded letter, commerce minister Anand Sharma shot off a letter to prime minister Manmohan Singh where he criticized the delay in the recommendations of the Maira Committee on foreign direct investment (FDI) in the pharma sector.On FDI in pharma, Shaw says,
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
